company overview

Paradigm is a healthcare technology company focused on improving access to clinical research for patients.

Paradigm is rebuilding the clinical research ecosystem by creating a technology-forward clinical trial platform that enables equitable access for all patients by enhancing trial efficiency and reducing the barriers to participation for healthcare providers.

Conceived by ARCH Venture Partners, and co-incubated by ARCH and General Catalyst, Paradigm publicly launched on January 25, 2023. monitoring and defense globally.

leadership

Kent Thoelke
CEO
Kent Thoelke previously served as Chief Innovation Officer at ICON plc, having formerly held the Chief Scientific Officer role with PRA Health Sciences prior to its acquisition by ICON. With 30 years in the drug development and clinical trials industry, Mr. Thoelke has had the opportunity to participate in all levels of drug research.  Having had the opportunity to work in biotech, pharma and the CRO industries, he brings a unique perspective to the modernization of clinical trials.  He has spent the last decade focused on the use of Real World Data and Technology to make clinical trials more accessible and drug development more efficient.

investment date

May 2022

Industry

Public Health/Life Sciences

headquarters

Seattle, Washington

website

paradigm.inc